Low-dose THC holds breast cancer cells in tumor models

Under the microscope, breast cancer organoids changed course after four days of low-dose THC, the cannabis compound tetrahydrocannabinol. When researchers washed the drug away, the three-dimensional tumor models did not return to their aggressive state. They remained more mature and luminal-like, resembling cells that line the breast’s milk ducts.

That matters because some breast cancer cells are flexible. They can move from a differentiated state back toward a stem-like identity, where they become more invasive and harder to treat. Nuria G. Martínez-Illescas and colleagues grew organoids from mouse breast tumors and patient samples to test whether that reversal could be held in check.

The mechanism narrowed to CB2R, one of two principal cannabinoid receptors in the endocannabinoid system — a network that helps regulate biological processes including cell differentiation. Turning down CB2R with an experimental compound produced the same mature, luminal-like state as THC; turning down CB1R had no effect. Cells from mice genetically lacking CB2R also showed less aggressive characteristics without drug treatment.

The effect was not merely immediate in the reported models. Treated organoids stayed in their more mature state over the long term, even when exposed to environmental stress signals that normally push cancer cells toward greater aggressiveness. The researchers associated the state with reduced stemness, impaired migration, less self-renewal and decreased metastatic potential, in vitro and in vivo.

So what changes, concretely? For patients, nothing yet: this was an early study in organoids and mice, not a human cancer treatment. For researchers, it identifies a possible strategy — briefly modulating CB2R to stabilize a less aggressive cell identity — that can now be tested against the limits of tumor biology and, eventually, clinical evidence.